以岭药业
(002603)
| 流通市值：230.90亿 | | | 总市值：280.18亿 |
| 流通股本：13.77亿 | | | 总股本：16.71亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,040,142,217.94 | 2,358,232,707.77 | 6,512,734,471.77 | 6,365,441,001.17 |
| 营业收入 | 4,040,142,217.94 | 2,358,232,707.77 | 6,512,734,471.77 | 6,365,441,001.17 |
| 二、营业总成本 | 3,245,278,851.39 | 1,946,902,188.1 | 7,147,123,381.22 | 5,723,859,252.05 |
| 营业成本 | 1,637,009,460.27 | 1,088,979,435.66 | 3,244,208,648.07 | 2,966,689,927.87 |
| 税金及附加 | 64,814,738.42 | 30,250,648.89 | 119,211,877.27 | 92,543,140.09 |
| 销售费用 | 913,223,536.33 | 547,039,894.43 | 2,334,704,305.07 | 1,672,009,793.12 |
| 管理费用 | 273,783,670.3 | 117,453,827.72 | 600,011,013.3 | 395,046,421.77 |
| 研发费用 | 358,284,639.01 | 164,030,341.5 | 826,572,646.79 | 571,912,835.78 |
| 财务费用 | -1,837,192.94 | -851,960.1 | 22,414,890.72 | 25,657,133.42 |
| 其中:利息费用 | 401,838.23 | 139,827.92 | 29,006,743.88 | 28,465,206.58 |
| 其中:利息收入 | 3,448,412.32 | 1,467,295.44 | 8,001,089.51 | 5,607,750.08 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | 38,863,277.79 |
| 加:投资收益 | -80,573.67 | -495,638.12 | 39,808,208.41 | 501,146.91 |
| 资产处置收益 | 14,191.17 | -87.07 | -487,181.84 | -1,763,045.54 |
| 资产减值损失(新) | -23,365,676.47 | -20,228,830.71 | -248,337,301.39 | -4,677,546.02 |
| 信用减值损失(新) | 1,210,238.46 | 2,150,899.78 | -10,297,019.75 | -17,641,197.58 |
| 其他收益 | 48,894,821.57 | 5,815,450.27 | 164,806,751.97 | 46,269,378.55 |
| 四、营业利润 | 821,536,367.61 | 398,572,313.82 | -688,895,452.05 | 703,133,763.23 |
| 加:营业外收入 | 7,972,964.98 | 6,268,964.61 | 10,472,588.05 | 2,499,457.21 |
| 减:营业外支出 | 25,855,573.05 | 10,720,228.07 | 121,769,143.83 | 33,524,829.83 |
| 五、利润总额 | 803,653,759.54 | 394,121,050.36 | -800,192,007.83 | 672,108,390.61 |
| 减:所得税费用 | 138,355,469.1 | 69,965,135.6 | -66,008,475.57 | 123,021,537.87 |
| 六、净利润 | 665,298,290.44 | 324,155,914.76 | -734,183,532.26 | 549,086,852.74 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 665,298,290.44 | 324,155,914.76 | -734,183,532.26 | 549,086,852.74 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 668,535,024.73 | 325,953,296.25 | -724,515,582.24 | 554,776,843.41 |
| 少数股东损益 | -3,236,734.29 | -1,797,381.49 | -9,667,950.02 | -5,689,990.67 |
| 扣除非经常损益后的净利润 | 641,355,642.22 | 325,059,321.37 | -792,499,673.79 | 507,253,130.69 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.4 | 0.2 | -0.43 | 0.33 |
| (二)稀释每股收益 | 0.4 | 0.2 | -0.43 | 0.33 |
| 八、其他综合收益 | -115,833.71 | -54,894.21 | -507,389.2 | 551,883.75 |
| 归属于母公司股东的其他综合收益 | -115,833.71 | -54,894.21 | -507,389.2 | 551,883.75 |
| 九、综合收益总额 | 665,182,456.73 | 324,101,020.55 | -734,690,921.46 | 549,638,736.49 |
| 归属于母公司股东的综合收益总额 | 668,419,191.02 | 325,898,402.04 | -725,022,971.44 | 555,328,727.16 |
| 归属于少数股东的综合收益总额 | -3,236,734.29 | -1,797,381.49 | -9,667,950.02 | -5,689,990.67 |
| 公告日期 | 2025-08-28 | 2025-04-29 | 2025-04-29 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |